INC Research Strengthens Cardiovascular Research Capabilities with Appointment of Dr. Martin Sullivan as Executive Medical Director, Cardiovascular Medicine
Distinguished cardiologist brings extensive experience in novel approaches for treating patients with cardiovascular disease
Raleigh, N.C., Oct. 14, 2013 - INC Research, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the appointment of Martin Sullivan, MD, as Executive Medical Director, Cardiovascular Medicine. Dr. Sullivan will leverage his strong therapeutic insight into clinical trials involving cardiovascular drugs and devices for a wide range of conditions to provide hands-on medical management of the Company's cardiology trials and to drive clinical development globally in this key therapeutic area.
"The prevalence of cardiovascular diseases provides significant opportunity for the development of new therapies to improve the health and overall wellbeing of many patients worldwide," said Sally Osmond, Executive Vice President and General Manager, Cardiovascular and Endocrinology Clinical Development at INC Research. "Marty is a highly respected cardiologist with extensive experience both in practice and in clinical development, having implemented more than 100 clinical research projects. We're thrilled to have a thought leader of his caliber to lead development of these complex trials."
Board-certified in both internal medicine and cardiovascular diseases, Dr. Sullivan brings more than 25 years of experience in medical practice and clinical research to INC Research. Prior to joining the Company, he worked as a research consultant specializing in noninvasive cardiology. He earned his medical degree at The Ohio State University and received his post-graduate cardiology training at Duke University where he remained on faculty, later becoming an Associate Professor of Medicine. Dr. Sullivan has had a long and distinguished career at a variety of institutions, including stints as the Director of the Duke Center for Integrative Medicine; Director of Cardiovascular Research at the Heartland Regional Medical Center in St. Joseph's, Missouri; and a Senior Research Consultant in the Division of Cardiology at the University of North Carolina. For his contributions to cardiovascular research, Dr. Sullivan was named an Established Investigator of the American Heart Association.
Dr. Sullivan will present "New Frontiers in Cardiovascular Research: Biologic Therapies - Using stem cells, gene therapy, and growth factors to treat patients with cardiovascular disease," a complimentary webinar, on Wednesday, Oct. 16, at 3 p.m. GMT/10 a.m. EDT. The webinar will cover the current state of research for cardiovascular diseases and will discuss novel approaches in clinical development, such as cell therapies, growth factors and gene therapies that are being used to regrow cells, repair damage and improve cardiovascular health without surgery. Click here to register.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
Posted: October 2013